Vaccine trials in melanoma—time for reflection (original) (raw)

Immunotherapy

Nature Reviews Clinical Oncology volume 6, pages 256–258 (2009)Cite this article

The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233–5239 (2008).
    Article CAS Google Scholar
  2. Eggermont, A. M. & Gore, M. Randomised adjuvant trials in melanoma: surgical and systemic. Semin. Oncol. 34, 509–515 (2007).
    Article Google Scholar
  3. Rosenberg, S. A. et al. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2004).
    Article CAS Google Scholar
  4. Smith, F. O. et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14, 5610–5618 (2008).
    Article CAS Google Scholar
  5. Sosman, J. A. et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol. 26, 2292–2298 (2008).
    Article CAS Google Scholar
  6. Eggermont, A. M. et al. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [Abstract]. ASCO Meeting Abstracts 26, 9004 (2008).
    Google Scholar
  7. Kirkwood, J. M. et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370–2380 (2001).
    Article CAS Google Scholar
  8. Schadendorf, D. et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC Study Group of the DeCOG. Ann. Oncol. 17, 563–570 (2006).
    Article CAS Google Scholar
  9. Maker, A. et al. Analysis of the cellular mechanism of antitumor response and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746–7754 (2005).
    Article CAS Google Scholar
  10. Gray, J. C. et al. Optimising anti-tumor CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 38, 2499–2511 (2008).
    Article CAS Google Scholar
  11. Eggermont, A. M. et al. Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumor effects of interleukin-2. Br. J. Cancer 56, 97–102 (1987).
    Article CAS Google Scholar
  12. Rosenberg, S. A. et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299–308 (2008).
    Article CAS Google Scholar

Download references

Author information

Author notes

  1. A. M. M. Eggermont, Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands a.eggermont@erasmusmc.nl

Authors and Affiliations

  1. Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, Rotterdam, The Netherlands
    Alexander M. M. Eggermont

Authors

  1. Alexander M. M. Eggermont

Ethics declarations

Competing interests

The author declared he is a consultant for the Schering–Plough Research Institute and receives research support from this organization.

Rights and permissions

About this article

Cite this article

Eggermont, A. Vaccine trials in melanoma—time for reflection.Nat Rev Clin Oncol 6, 256–258 (2009). https://doi.org/10.1038/nrclinonc.2009.42

Download citation

This article is cited by